Skip to main content

Table 2 Summary of clinical trials targeting CD47 with SIRPα-Fc fusion protein

From: Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed

SIRPα-Fc fusion

Company

IgG

Indications

Monotherapy or Combination

Phage stage

Clinical trials NO.

Status

Evorpacept

(ALX148)

Alex

Therapeutic

mutated SIRPα-Fc IgG1

Metastatic Cancer, Solid Tumor, Advanced Cancer, NHL

monotherapy, Pembrolizumab, Trastuzumab, rituximab, Pembrolizumab+ 5-FU + Cisplatin, Trastuzumab+Ramucirumab+Paclitaxel

Phase I

NCT03013218

174 participants,

Active, not recruiting

Higher Risk Myelodysplastic Syndrome

Azacitidine

Phase I

NCT04417517

173 participants,

Recruiting

HNSCC

Pembrolizumab

Phase II

NCT04675294

183 participants,

Recruiting

HNSCC

Pembrolizumab+Cisplatin/Carboplatin+5FU

Phase II

NCT04675333

168 participants,

AML

Venetoclax, Azacitidine

Phase I/II

NCT04755244

97 participants,

Recruiting

HER2+ gastric cancer

Trastuzumab, Ramucirumab, Paclitaxel

Phase II/III

NCT05002127

450 participants,

Recruiting

Indolent and Aggressive B-Cell Non-Hodgkin Lymphoma

Lenalidomide+Rituximab

Phase I/II

NCT05025800

52 participants, Recruiting

HER2+ gastric cancer

Zanidatamab

Phase Ib/II

NCT05027139

93 participants, Recruiting

Microsatellite Stable Metastatic Colorectal Cancer

Cetuximab+Pembrolizumab

Phase II

NCT05167409

80 participants, Not yet recruiting

TTI-621

Trillium

Therapeutics

SIRPα-Fc

IgG1

Hematologic Malignancies and Selected Solid Tumors

monotherapy, Rituximab and Nivolumab

Phase I

NCT02663518

260 participants,

Recruiting

R/R Solid Tumors and Mycosis Fungoides

monotherapy, PD-1/PD-L1 Inhibitor, pegylated interferon-α2a, T-Vec, radiation

Phase I

NCT02890368

56 participants,

terrminated

Leiomyosarcoma

Doxorubicin

Phase I/II

NCT04996004

80 participants,

Recruiting

Multiple Myeloma

Daratumumab Hyaluronidase-fihj

Phase I

NCT05139225

40 participants,

Recruiting

TTI-622

SIRPα-Fc

IgG4

Lymphoma, myeloma

monotherapy, Rituximab, PD-1 Inhibitor, Proteasome-inhibitor Regimen

Phase I

NCT03530683

150 participants,

Recruiting

Multiple Myeloma

Daratumumab Hyaluronidase-fihj

Phase I

NCT05139225

40 participants,

Recruiting

Platinum-Resistant Ovarian Cancer

Pegylated Liposomal Doxorubicin

Phase I/II

NCT05261490

50 participants,

Recruiting

IMM01

ImmunoOnco

mutated SIRPα-Fc IgG1

AML, MDS

Azacitidine

Phase I/II

NCT05140811

76 participants,

Not yet recruiting